Functional Coupling of the G_αolf Variant XLG_αolf with the Human Adenosine A_2A Receptor

REFERENCES

• Moreau J L, Huber G. Central adenosine A(2A) receptors: An overview. Brain Res Rev 1999; 31: 65–82, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sullivan G W. Adenosine A2A receptor agonists as anti-inflammatory agents. Curr Opin Investig Drugs 2003; 4: 1313–1319, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Klotz K N, Hessling J, Hegler J, Owman C, Kull B, Fredholm B B, Lohse M J. Comparative pharmacology of human adenosine receptor subtypes—Characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 1998; 357: 1–9, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tang Y, Luo J, Fleming C R, Kong Y, Olini G C, Jr, Wildey M J, Cavender D E, Demarest K T. Development of a sensitive and HTS-compatible reporter gene assay for functional analysis of human adenosine A2a receptors in CHO-K1 cells. Assay Drug Dev Technol 2004; 2: 281–289, [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Corvol J C, Studler J M, Schonn J S, Girault J A, Herve D. Galpha(olf) is necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum. J Neurochem 2001; 76: 1585–1588, [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Belluscio L, Gold G H, Nemes A, Axel R. Mice deficient in G(olf) are anosmic. Neuron 1998; 20: 69–81, [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Herve D, Le Moine C, Corvol J C, Belluscio L, Ledent C, Fienberg A A, Jaber M, Studler J M, Girault J A. Galpha(olf) levels are regulated by receptor usage and control dopamine and adenosine action in the striatum. J Neurosci 2001; 21: 4390–4399, [INFOTRIEVE], [CSA]
   Google Scholar
• Zhuang X, Belluscio L, Hen R. G(olf)alpha mediates dopamine D1 receptor signaling. J Neurosci 2000; 20: RC91, [INFOTRIEVE], [CSA]
   Google Scholar
• Berrettini W H, Ferraro T N, Goldin L R, Weeks D E, Detera-Wadleigh S, Nurnberger J I, Jr., Gershon E S. Chromosome 18 DNA markers and manic-depressive illness: Evidence for a susceptibility gene. Proc Natl Acad Sci USA 1994; 91: 5918–5921, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Schwab S G, Hallmayer J, Lerer B, Albus M, Borrmann M, Honig S, Strauss M, Segman R, Lichtermann D, Knapp M, Trixler M, Maier W, Wildenauer D B. Support for a chromosome 18p locus conferring susceptibility to functional psychoses in families with schizophrenia, by association and linkage analysis. Am J Hum Genet 1998; 63: 1139–1152, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Corradi J P, Ravyn V, Robbins A K, Hagan K W, Peters M, Bostwick R, Buono R, Berrettini W, Furlong S. Alternative transcripts and evidence of imprinting of GNAL on 18p11.2. Molecular Psychiatry 2005; 10: 1017–1025, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Cheng Y, Prusoff W H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099–3108, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Robeva A S, Woodard R, Luthin D R, Taylor H E, Linden J. Double tagging recombinant A1- and A2A-adenosine receptors with hexahistidine and the FLAG epitope. Development of an efficient generic protein purification procedure. Biochem Pharmacol 1996; 51: 545–555, [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Bouvier M, Menard L, Dennis M, Marullo S. Expression and recovery of functional G-protein-coupled receptors using baculovirus expression systems. Curr Opin Biotechnol 1998; 9: 522–527, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rosin D L, Robeva A, Woodard R L, Guyenet P G, Linden J. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol 1998; 401: 163–186, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Piersen C E, True C D, Wells J N. A carboxyl-terminally truncated mutant and nonglycosylated A2a adenosine receptors retain ligand binding. Mol Pharmacol 1994; 45: 861–870, [INFOTRIEVE], [CSA]
   Google Scholar
• DeMet E M, Chicz-De Met A. Localization of adenosine A2A-receptors in rat brain with [3H]ZM-241385. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 478–481, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zocchi C, Ongini E, Ferrara S, Baraldi P G, Dionisotti S. Binding of the radioligand [3H]-SCH 58261, a new non-xanthine A2A adenosine receptor antagonist, to rat striatal membranes. Br J Pharmacol 1996; 117: 1381–1386, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ongini E, Dionisotti S, Gessi S, Irenius E, Fredholm B B. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 1999; 359: 7–10, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sihver W, Bier D, Holschbach M H, Schulze A, Wutz W, Olsson R A, Coenen H H. Binding of tritiated and radioiodinated ZM241,385 to brain A2A adenosine receptors. Nucl Med Biol 2004; 31: 173–177, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Beukers M W, Wanner M J, Von Frijtag Drabbe Kunzel J K, Klaasse E C, AP I J, Koomen G J. N6- cyclopentyl-2-(3-phenylaminocarbonyltriazene-1yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor. J Med Chem 2003; 46: 1492–1503, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dionisotti S, Ongini E, Zocchi C, Kull B, Arslan G, Fredholm B B. Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261. Br J Pharmacol 1997; 121: 353–360, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Gao Z, Li Z, Baker S P, Lasley R D, Meyer S, Elzein E, Palle V, Zablocki J A, Blackburn B, Belardinelli L. Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther 2001; 298: 209–218, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Harvey V, Jones J, Misra A, Knight A R, Quirk K. Solubilisation and immunoprecipitation of rat striatal adenosine A(2A) receptors. Eur J Pharmacol 2001; 431: 171–177, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Varani K, Gessi S, Dalpiaz A, Ongini E, Borea P A. Characterization of A2A adenosine receptors in human lymphocyte membranes by [3H]-SCH 58261 binding. Br J Pharmacol 1997; 122: 386–392, [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Gessi S, Varani K, Merighi S, Ongini E, Borea P A. A(2A) adenosine receptors in human peripheral blood cells. Br J Pharmacol 2000; 129: 2–11, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kull B, Arslan G, Nilsson C, Owman C, Lorenzen A, Schwabe U, Fredholm B B. Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochem Pharmacol 1999; 57: 65–75, [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Fredholm B B, Irenius E, Kull B, Schulte G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 2001; 61: 443–448, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hirschhorn R, Roegner-Maniscalco V, Kuritsky L, Rosen F S. Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients. J Clin Invest 1981; 68: 1387–1393, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Daly J W, Padgett W L, Secunda S I, Thompson R D, Olsson R A. Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. Pharmacology 1993; 46: 91–100, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gao Z G, Jiang Q, Jacobson K A, IJzerman A P. Site-directed mutagenesis studies of human A(2A) adenosine receptors: Involvement of glu(13) and his(278) in ligand binding and sodium modulation. Biochem Pharmacol 2000; 60: 661–668, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kim J, Jiang Q, Glashofer M, Yehle S, Wess J, Jacobson K A. Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. Mol Pharmacol 1996; 49: 683–691, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Jiang Q, Lee B X, Glashofer M, van Rhee A M, Jacobson K A. Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. J Med Chem 1997; 40: 2588–2595, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Murphree L J, Marshall M A, Rieger J M, Macdonald T L, Linden J. Human A(2A) adenosine receptors: High-affinity agonist binding to receptor-G protein complexes containing Gbeta(4). Mol Pharmacol 2002; 61: 455–462, [INFOTRIEVE], [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Cohen F R, Lazareno S, Birdsall N J. The effects of saponin on the binding and functional properties of the human adenosine A1 receptor. Br J Pharmacol 1996; 117: 1521–1529, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Ciruela F, Saura C, Canela E I, Mallol J, Lluis C, Franco R. Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors. FEBS Lett 1996; 380: 219–223, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Herrera C, Casado V, Ciruela F, Schofield P, Mallol J, Lluis C, Franco R. Adenosine A2B receptors behave as an alternative anchoring protein for cell surface adenosine deaminase in lymphocytes and cultured cells. Mol Pharmacol 2001; 59: 127–134, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Cristalli G, Vittori S, Thompson R D, Padgett W L, Shi D, Daly J W, Olsson R A. Inhibition of platelet aggregation by adenosine receptor agonists. Naunyn Schmiedebergs Arch Pharmacol 1994; 349: 644–650, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Daly J W, Padgett W L. Agonist activity of 2- and 5′-substituted adenosine analogs and their N6-cycloalkyl derivatives at A1- and A2-adenosine receptors coupled to adenylate cyclase. Biochem Pharmacol 1992; 43: 1089–1093, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• van Tilburg E W, Gremmen M, Frijtag Drabbe K J, de Groote M, IJzerman A P. 2, 8-Disubstituted adenosine derivatives as partial agonists for the adenosine A2A receptor. Bioorg Med Chem 2003; 11: 2183–2192, [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Jasper J R, Lesnick J D, Chang L K, Yamanishi S S, Chang T K, Hsu S A, Daunt D A, Bonhaus D W, Eglen R M. Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. Biochem Pharmacol 1998; 55: 1035–1043, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Umland S P, Wan Y, Shah H, Billah M, Egan R W, Hey J A. Receptor reserve analysis of the human alpha(2C)-adrenoceptor using [35S] GTPγS and cAMP functional assays. Eur J Pharmacol 2001; 411: 211–221, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar